Circulating CD22+CD20-CD19+ cells at baseline may predict the clinical response 
to rituximab in patients with active RA.

Owczarczyk, K.; Passon, D.; Roehrs, T.; Jung, N.; Taubert, D.; Valet, G.; Rubbert, A.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Circulating CD22+CD20-CD19+ cells at baseline may predict the clinical response to rituximab in patients with active RA.

MPS-Authors

/persons/resource/persons78821

Valet, G.
Former Research Groups, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Owczarczyk, K., Passon, D., Roehrs, T., Jung, N., Taubert, D., Valet, G., et al. (2007). Circulating CD22+CD20-CD19+ cells at baseline may predict the clinical response to rituximab in patients with active RA. Zeitschrift fur Rheumatologie, 66(Suppl. Suppl. 1), 40-40.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-5F3A-0

Abstract

There is no abstract available